ABSTRACT
The aim of this work is to study the structural, dielectric, and mechanical properties of aluminum oxide ceramics with the triple sintering additive 4CuO-TiO2-2Nb2O5. With an increase in sintering temperature from 1050 to 1500 °C, the average grain size and the microhardness value at a load of 100 N (HV0.1) increased with increasing density. It has been shown that at a sintering temperature of 1300 °C, the addition of a 4CuO-TiO2-2Nb2O5 additive increases the low-frequency permittivity (2-500 Hz) in alumina ceramic by more than an order of magnitude due to the presence of a quadruple perovskite phase. At the same time, the density of such ceramics reached 89% of the theoretical density of α-Al2O3, and the microhardness value HV0.1 was 1344. It was observed that the introduction of 5 wt.% 4CuO-TiO2-2Nb2O5 in the raw mixture remarkably increases values of shrinkage and density of sintered ceramics. Overall, the results of this work confirmed that introducing the 4CuO-TiO2-2Nb2O5 sintering additive in the standard solid-phase ceramics route can significantly reduce the processing temperature of alumina ceramics, even when micron-sized powders are used as a starting material. The obtained samples demonstrated the potential of α-Al2O3 with the triple additive in such applications as electronics, microwave technology, and nuclear power engineering.
ABSTRACT
We report combined therapy using upconversion nanoparticles (UCNP) coupled to two therapeutic agents: beta-emitting radionuclide yttrium-90 (90Y) fractionally substituting yttrium in UCNP, and a fragment of the exotoxin A derived from Pseudomonas aeruginosa genetically fused with a targeting designed ankyrin repeat protein (DARPin) specific to HER2 receptors. The resultant hybrid complex UCNP-R-T was tested using human breast adenocarcinoma cells SK-BR-3 overexpressing HER2 receptors and immunodeficient mice, bearing HER2-positive xenograft tumors. The photophysical properties of UCNPs enabled background-free imaging of the UCNP-R-T distribution in cells and animals. Specific binding and uptake of UCNP complexes in SK-BR-3 cells was observed, with separate 90Y- and PE40-induced cytotoxic effects characterized by IC50 140 µg/mL (UCNP-R) and 5.2 µg/mL (UCNP-T), respectively. When both therapeutic agents were combined into UCNP-R-T, the synergetic effect increased markedly, â¼2200-fold, resulting in IC50 = 0.0024 µg/mL. The combined therapy with UCNP-R-T was demonstrated in vivo.
